ThirdLaw Molecular Inc. Launches its Groundbreaking Platform for Targeted Drug Discovery with a 4.5-Billion Molecule DNA-Encoded Library of Spiroligomer™ Macromolecules
- ThirdLaw Molecular has pioneered the development of Spiroligomer™ molecules – an entirely new, synthetic, therapeutic modality that reimagines molecular therapeutics
- Spiroligomer™ molecules combine the high selectivity of biologics with the best drug-like properties of small molecules with the simplicity of synthesis of peptides and DNA
- Unveiling the next frontier in drug discovery and therapeutic innovation
PHILADELPHIA, Jan. 9, 2025 /PRNewswire/ -- ThirdLaw Molecular Inc., a targeted drug discovery biotech reimagining molecular therapeutics, today announced the launch of its first DNA-encoded library of 4.5 billion Spiroligomer™ macromolecules. This library provides the Company and prospective partners access to a revolutionary category of molecules and the potential to transform how diseases are diagnosed and treated.
Advantages of Spiroligomer™-Based Molecules
Spiroligomer™-based molecules represent an entirely new therapeutic modality and are designed to overcome the limitations of traditional small molecules and biologics:
- Advantages over small molecules: Complex, modular, fused-ring, natural-product-like, pre-programmed structures; highly selective; fewer "off-target" effects; potential to address "undruggable" targets
- Advantages over biologics: Cell permeable; orally bioavailable; potential for improved pharmacokinetics; low immunogenicity risk; simple, scalable manufacture; stable with no special storage and handling
"Spiroligomer™ technology combines the best features of both biologics and small molecules," said Christian Schafmeister, PhD, Founder and President of ThirdLaw Molecular. "The molecules have complex structures that allow them to selectively target proteins of interest. Yet they are small enough to penetrate cells, have favorable drug-like properties, and are synthetic in origin, making them easy to manufacture and store".
Accelerating Discovery of Novel Therapeutics
The availability of this 4.5-billion-member DNA-encoded library of Spiroligomer™ macromolecules allows for rapid and efficient screening against biologic targets of interest. The modular design of the molecules enables rapid validation of hits, optimization of drug properties, and accelerated identification of potential lead candidates for development. Selective nanomolar-level binding of Spiroligomer™-based molecules with target proteins of commercial interest has already been demonstrated using this approach, representing a major milestone in the development of this groundbreaking therapeutic modality.
A Platform for Collaboration and Innovation
ThirdLaw Molecular officially opens the door to partnership opportunities with pharmaceutical companies. These collaborations will harness the platform's potential and accelerate the development of novel therapeutics across a broad range of diseases, including those previously considered undruggable.
J. David Owens, Board Member of ThirdLaw Molecular, commented, "This represents an inflection point in the Company's progress – and in therapeutic innovation itself. Spiroligomer™ macromolecules have the potential to redefine how we treat diseases, offering new hope to patients, and we look forward to advancing this disruptive technology to realize its promise."
About ThirdLaw Molecular
ThirdLaw Molecular is a targeted drug discovery company that is reimagining molecular therapeutics by pioneering the development of Spiroligomer™ technology. This is a novel, patent-protected chemical platform of synthetic, modular, fused-ring structures incorporating a diverse range of functional groups, allowing exquisite control of molecular shapes. The Company is designing and synthesizing searchable libraries of billions of these unique, chemically distinctive, compounds for highly selective binding of proteins of biologic interest – including those previously considered undruggable. Spiroligomer™-based molecules offer selectivity, cell permeability, oral bioavailability, protease resistance, and scalable synthesis. Combined with ThirdLaw Molecular's computational design expertise, they represent a promising source of safe, effective therapeutics, both for partnerships and the Company's pipeline. For more information, visit www.thirdlawtx.com and follow us on X and LinkedIn.
Media Contact:
Alison Guzzio
484-459-3243
Alison.guzzio@thirdlaw.tech
View original content:SOURCE ThirdLaw Molecular